# Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

> **NCT00004889** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00004889
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2002-01
- **Final completion:** 2005-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004889, "Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*